Traditional drug development for ion channels has predominantly focused on small molecules. While effective, this approach often encounters challenges, particularly with selectivity and safety. Biologics, including toxins and venom-derived peptides, have emerged as a promising alternative to address these limitations. Animal toxins have long been invaluable in ion channel research, offering insights into their structure, function, and gating mechanisms. Venoms are now recognized as a rich resource for innovative research tools and therapeutic leads. Peptide-based drugs, derived from these venoms, have gained attention for their unique advantages, such as larger interaction surfaces that confer greater specificity and selectivity compared to small molecules.